financetom
Business
financetom
/
Business
/
Frontera says Guyana oil license remains valid amid government cancellation notice
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Frontera says Guyana oil license remains valid amid government cancellation notice
Mar 10, 2025 11:27 AM

March 10 (Reuters) - Canadian oil producer Frontera

Energy ( FECCF ) said on Monday that it believes its license to

explore the Corentyne block off the coast of Guyana remains

valid and it is assessing all legal options to assert its

rights.

The Guyanese government gave Frontera and CGX Energy ( CGXEF )

, the joint operators that hold the license, a 30-day

cancellation notice over unmet contract obligations.

The Corentyne block was seen as a key effort to diversify

Guyana's oil industry, currently dominated by a consortium led

by Exxon Mobil ( XOM ).

It is also the only area Frontera and CGX Energy ( CGXEF ) -

the joint operators that hold the license - have left in Guyana

after they returned two other blocks in recent years over budget

constraints.

The Guyanese government had given the joint venture

until February 22 to submit arguments for reconsideration. The

license is set to expire on March 10 unless their

representations are favorably reviewed.

Frontera Energy ( FECCF ) reported its quarterly and yearly earnings

on Monday, showing a nearly 8% increase in fourth-quarter

production compared to the same quarter last year, reaching

42,406 barrels of oil equivalent per day (boed).

However, shares fell 4.1% in afternoon trade as the company

posted a net loss of $29.4 million, or 36 cents per share,

compared to a net income of $92.0 million, or $1.08 per share,

in the fourth quarter of 202

The Calgary, Canada-based company expects to produce 40,400

boed in the first quarter of this year to due to unexpected well

failures within its light and medium assets, which the company

says it was addressing.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ryvyl Launches Stock Offering; Shares Drop After-Hours
Ryvyl Launches Stock Offering; Shares Drop After-Hours
Apr 15, 2024
05:36 PM EDT, 04/15/2024 (MT Newswires) -- Ryvyl ( RVYL ) said late Monday it has launched a public offering of an undisclosed number of its shares. The company plans to grant a 45-day overallotment option to its underwriter to acquire up to an additional 15% of the number of shares sold in the offering. Joseph Gunnar is the book-running...
Western Copper and Gold Prices $25 Million Bought-Deal Public Offering
Western Copper and Gold Prices $25 Million Bought-Deal Public Offering
Apr 15, 2024
05:36 PM EDT, 04/15/2024 (MT Newswires) -- Western Copper and Gold ( WRN ) said Monday that Eight Capital agreed to buy about 13.2 million shares of the company on a bought-deal basis. Eight Capital, which represents a syndicate of underwriters, will pay $1.90 per share for gross proceeds of about $25 million, the company added. Western Copper said it...
GreenFirst Forest Products Inc. Announcing
GreenFirst Forest Products Inc. Announcing "Significant" Reduction in SG&A and Overhead Expenses
Apr 15, 2024
05:33 PM EDT, 04/15/2024 (MT Newswires) -- GreenFirst Forest Products Inc. ( ICLTF ) after trade Monday announced significant initiatives to reduce its selling, general, and administrative and overhead expenses to improve the company's cost-competitiveness for the long term. Compared to 2023, on an annualized basis, it said the initiatives are projected to significantly decrease SG&A and overhead costs resulting...
Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'
Zevra Therapeutics Metabolic Disorder Treatment Shows 'Meaningful Slowing of Disease Progression'
Apr 15, 2024
05:35 PM EDT, 04/15/2024 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) disclosed late Monday new data from the arimoclomol expanded access program to treat Niemann-Pick disease type C, an inherited metabolic disorder, demonstrated a clinically meaningful slowing of disease progression. Chief Executive Neil McFarlane said the company will continue collaborating with the US Food and Drug Administration as it...
Copyright 2023-2026 - www.financetom.com All Rights Reserved